Barrington raised the firm’s price target range on Paysign (PAYS) to $8-$9 from a prior range of $6-$7 and keeps an Outperform rating on the shares. The firm cites the “strong outlook” for Paysign’s Patient Affordability segment for the pharmaceutical industry for its target hike.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAYS:
- Strategic Positioning and Growth Potential: PaySign’s Role in Pharmaceutical Patient Affordability
- Paysign price target raised to $9 from $7 at Lake Street
- Paysign management to meet with Lake Street
- DA Davidson research director holds a bison roundup conference call
- 3 Best Stocks to Buy Now, 6/16/2025, According to Top Analysts